Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06376045 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
A Phase 2 study of Asthma, sponsored by Amgen.
- Active
- Registry status
- Phase 2
- Development phase
- 317
- Enrollment target
- 20
- Study locations
NCT06376045 is a Phase 2 study of Asthma that is active but no longer recruiting, run by Amgen. The registered enrollment target is 317 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT06376045, a Phase 2 study of Asthma, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 317 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rocatinlimab
Study Locations (20)
California
- Kern Research Inc - Bakersfield
- Orso Health Inc - La Jolla
- Imax Clinical Trials - La Palma
- Antelope Valley Clinical Trials - Lancaster
- Downtown Los Angeles Research Center, Inc - Los Angeles
- NewportNativeMD, Inc - Newport Beach
- University of California Irvine - Orange
- Apex Clinical Research - San Diego
- Allergy and Asthma Clinical Research - Walnut Creek
- Allianz Research Institute Westminster - Westminster
Florida
- St Francis Medical Institute - Clearwater
- BioMed Research Institute - Miami
- Bright Research Center LLC - Miami
- Infinity Life Research Group - Tamarac
- Clinical Research Trials of Florida Inc - Tampa
Georgia
- AllerVie Clinical Research- Columbus - Columbus
Idaho
- Treasure Valley Medical Research - Boise
Illinois
- Sneeze, Wheeze, and Itch Associates, LLC - Normal
Kentucky
- Family Allergy and Asthma Research Institute - Louisville
Maryland
- Chesapeake Clinical Research Inc - White Marsh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 317 participants |
| Start Date | 2024-05-24 |
| Est. Completion | 2026-12-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06376045
The ClinicalTrials.gov registry entry for NCT06376045 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 317 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (80% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06376045 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06376045 about?
NCT06376045 is a clinical study titled "A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma". The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.
What is the current status of trial NCT06376045?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 317 participants. The study started on 2024-05-24. Estimated completion is 2026-12-11.
What conditions does trial NCT06376045 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT06376045?
The interventions under investigation include: Placebo (DRUG), Rocatinlimab (DRUG).
Who is sponsoring clinical trial NCT06376045?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06376045 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.